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Abstract 
Objective: To assess the bleeding profile, acceptance and safety of an extended 126-day regimen of the oral 
contraceptive Yasmin® [30 µg ethinylestradiol (EE) and 3 mg drospirenone (DRSP)]. 
Methods: Using daily diaries, 177 women recorded bleeding events throughout the 126-day cycle. At end of 
treatment, the women completed questionnaires reflecting their satisfaction with the extended regimen. A subset 
of 30 women underwent endometrial histology sampling after completion of the extended regimen. 
Results: Of 177 women assigned to the extended regimen, 80.8% completed the extended 126-day regimen. 
Approximately 40% of the women reported complete absence of bleeding, while in 60% a shift towards less 
intense bleeding was observed. The first onset of bleeding occurred after a median of 99.0 days into the extended 
cycle. The acceptance of the extended regimen was high, with 68.4% of the women expressing satisfaction. The 
general safety profile with the extended use was comparable to that seen with the conventional 21+7-day 
regimen. All endometrial biopsies with sufficient material for analysis were normal and supported the 
endometrial safety of the extended regimen. 
Conclusion: This study showed that the continuous use of a 30-µg EE and 3-mg DRSP formulation over 126 
days was safe, efficacious, well 
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1. INTRODUCTION 
To date, most combination oral contraceptives (COCs) include a dosage regimen that induces withdrawal 
bleeding every 4 weeks. This concept was first introduced by Dr. Gregory Pincus in the late 1950s in order to 
mimic the natural "lunar" cycle that usually lasts between 25 and 30 days [1]. The administration of COCs in a 
21-day cycle of active hormone pills followed by a 7-day pill-free interval produces predictable withdrawal 
bleeding in most users. 
However, there is no scientific rationale for the 21+7-day cycle as the only regimen for COCs [2]. Prolonged 
intervals between withdrawal bleedings are established with long-acting contraceptive injectables, implants or 
progestogen-containing intrauterine devices. In fact, almost 30 years ago it was shown that the pill too has the 
ability to control the pattern of uterine bleeding beyond 3 weeks without compromising its contraceptive efficacy 
[3]. 
In actual clinical practice, the continuous administration of COC is often recommended to women to postpone 
withdrawal bleeding for medical reasons such as dysmenorrhea, excessive blood loss or hormone withdrawal 
symptoms, and for personal reasons such as holidays or sports [4]. Meanwhile, numerous studies on this issue 
have been performed proving that an extended regimen is initially associated with an increased rate of irregular 
bleeding, while the total number of bleeding days can be reduced significantly [5-8]. Reports of extended cycle 
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regimens in an actual clinical practice have confirmed the acceptance of delaying the onset of withdrawal 
bleeding and associated hormone withdrawal symptoms [9,10]. Recent surveys revealed that women indeed 
accept this concept. When queried, 65% of Dutch women between 25 and 34 years preferred bleeding every 3 
months or less often, and 31% preferred not to bleed [11]. Although extended COC regimens are commonly 
recommended by physicians, only in the USA is OC available that is specifically labeled for 84 days of extended 
use [5-8,12]. 
We initiated this study to investigate the bleeding pattern, efficacy and safety of a 126-day extended regimen, 
and to test whether extension beyond 3 months is a favorable treatment option for COC users. The 126-day 
extended regimen consists of a known combination of 30 µg ethinylestradiol (EE) and 3 mg drospirenone 
(DRSP) (Yasmin®, Schering) at a dose level of proven efficacy and safety [13,14]. Because this formulation has 
been shown to reduce water retention, weight gain, premenstrual symptoms and skin disorders such as acne 
when used in a 21+7-day fashion, it was chosen as a possible ideal candidate for an extended cycle regimen [15-
17]. 
2. MATERIAL AND METHODS 
2.1. Study design and population 
This was a prospective, multicenter, open, uncontrolled study of the 126-day extended regimen of the oral 
contraceptive Yasmin® (30 µg EE and 3 mg DRSP). The study was conducted from May 2002 to January 2004 
at 10 study centers in Belgium, Denmark, Sweden and Norway, consisting of private practices and university-
affiliated clinics. The study protocol was approved by appropriate ethics committees of the participating study 
sites and was conducted in accordance with the ethical principles that have their origin in the Declaration of 
Helsinki and the ICH-GCP Guidelines of 17 January 1997. 
Women were excluded for age less than 18 years or greater than 35 years (maximum age for smokers was 30 
years), current OC use of less than six cycles and standard contraindications to COC use. After the written 
informed consent was obtained, information on demographics, medical and gynecological history, OC use 
history and concomitant medication was collected. Height, weight and blood pressure were obtained along with a 
physical and gynecological examination, including a Papanicolaou smear if no normal result in the last 3 months 
was available. 
2.2. Treatment and procedures 
In order to prevent carryover effects from any preceding COC, the women switched to two 21+7-day run-in 
cycles of the EE/DRSP formulation before beginning the extended cycle. After completion of the run-in cycles, 
the women were advised to continue daily tablet intake without any tablet-free intervals for 126 days. The 
women were to record the daily pill intake and vaginal bleeding in their diary cards. 
Women returned for clinic visits every 6 weeks and at study exit, except for one phone visit after 6 weeks of 
continuous use. They were instructed to bring their diary cards and empty pill packs to each visit. Investigators 
verified the diary records and signed for completeness and plausibility. Vital signs, adverse events and changes 
in concomitant medication were assessed at each visit. A thorough physical and gynecological examination 
including a Papanicolaou smear was performed at study exit. At end of treatment, the women completed a 
questionnaire to assess their satisfaction with the treatment using a seven-point scale ranging from "very much," 
"much," "minimally," "neither/nor," "satisfied" to "minimally," "much" and "very much dissatisfied." They were 
also asked which treatment option they would prefer for future use (extended regimen, conventional 21+7-day 
cycle or other options including other regimens or other methods of contraception). 
After completion of the 126-day cycle, women could either exit the study or continue with the extended regimen 
for another 126-day cycle without any break. One participating study center was randomly selected to perform 
endometrial biopsies on women who had completed the 252-day regimen and volunteered to sampling. A single 
pathologist scored the specimen for adequacy and histologic findings. The results were classified as insufficient 
material, normal/nonsuspicious or abnormal. 
2.3. Efficacy assessments and analysis 
Efficacy measures were primarily based on bleeding patterns such as time to first bleeding day (requiring 
sanitary protection), number of bleeding or spotting days, and the maximum bleeding intensity. The bleeding 
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intensity for any given day was scored (none, spotting=no sanitary protection needed, light=less than associated 
with normal menstruation with need for sanitary protection, normal=like normal menstruation, heavy=more than 
normal menstruation). For each woman, the bleeding patterns were analyzed for the entire 126-day cycle, and for 
the World Health Organization (WHO)-recommended reference period of 90 days; assessing the first 90 days of 
the 126-day interval [18]. In addition, the number of women with missed pills, the treatment acceptance and the 
preferred regimen options for future use were analyzed. Safety measures included adverse event reports and 
general safety assessments such as gynecological examinations, cervical smears and endometrial biopsies. All 
collected data were computerized and stored in an Oracle database. The data organization and the statistical 
evaluation of the clinical trial were performed using the statistical software package SAS 8.2 on a Windows 
platform. All variables were analyzed by adequate descriptive statistics, i.e., number of observations, mean, 
standard deviation, minimum, median, maximum for continuous data and frequency tables for categorical data. 
No hypotheses have been stated. 
3. RESULTS 
3.1. Study population and disposition 
A total of 184 women—all of them current OC users— were recruited and treated across 10 study centers. The 
enrollment demographics and baseline characteristics of the study population are displayed in Table 1. The great 
majority of women were Caucasian (98.4%) and non-smokers (76.1%). They were 23.7 ± 4.1 years old (mean ±  
SD). At time of enrollment, the women rated their monthly withdrawal bleeding as predominantly normal in 
intensity. The duration of the monthly bleeding varied from 2 to 8 days (4.7 ± 1.0 days). 
Three of 184 women taking study medication were lost to follow-up. Of the remaining 181, 175 were assigned to 
run-in cycles, while 6 omitted the run-in as they were already taking the study medication for at least two cycles. 
An overview of study completion rates and reasons for dropout is given in Fig. 1. Of 177 women admitted to the 
126-day cycle, 143 (80.8%) completed the extended regimen. The most common reason for premature 
discontinuation was adverse events, most frequently specified as bleeding. With completion of the 126-day 
cycle, women were given the option to either stop or continue the extended regimen for another 126 days. 
All 177 women, who received at least one dose of the 126 - day regimen and for whom diary information was 
available, were included in the analysis of the compliance, bleeding pattern, acceptance of extended regimen and 
safety. 
Table 1- Enrollment demographic information (full analysis set) 
Characteristics Extended cycle (N= 184) 
Race 
   Caucasian, n (%) 181 (98.4) 
   Hispanic, n (%) 1 (0.5) 
   Asian, n (%) 2 (1.1) 
Mean age, years (SD) 23.7 (4.1) 
Mean BMIa (SD); range (kg/m2) 22.0 (3.1); 15.8-31.4 
Current smokers, n (%) 44 (23.9) 
Withdrawal bleeding  
   Mean lengths (SD); range (days) 4.7 (1.0); 2-8 
   Light intensityb , n (%) 45 (24.5) 
   Normal intensityb , n (%) 128 (69.6) 
   Heavy intensityb , n (%) 11 (6.0) 
a BMI=Body mass index. 
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Fig. 1. Study population flow chart and reasons for discontinuation. 
 
 
3.2. Compliance and contraceptive reliability 
Based on the women's diary study medication records, pill compliance within the 126-day regimen was 
measured as the number of women missing more than two tablets continuously, or as the number of women 
missing more than four tablets noncontinuously. A total of 19 women (10.7%) were deemed noncompliant. No 
pregnancy was reported during the entire course of the study. 
3.3. Bleeding pattern 
All bleeding information, from run-in phase throughout the extended 126-day regimen, was derived from the 
women's daily diary entries using established criteria for different bleeding patterns. Accordingly, Fig. 2 presents 
the percentage of women who reported bleeding by cycle day. During the run-in phase, two withdrawal bleeding 
episodes were expected to occur, while during the extended regimen any bleeding or spotting was considered 
unscheduled (breakthrough) bleeding/spotting. The per-day analysis indicated that the percentage of women 
reporting unscheduled bleeding increased slightly within the first 50 days, but then seemed to plateau in the 
further course of the extended regimen. Furthermore, the per-day analysis revealed that more than half of the 
women had started the extended regimen while the scheduled withdrawal bleeding from run-in persisted. As a 
result of this, there was an overlap of withdrawal bleeding of the second run-in cycle into the first 2 weeks of the 
extended regimen. For the analysis of the first onset of breakthrough bleeding and its intensity, it was decided to 
disregard these 2 weeks of the extended regimen. 
Table 2 summarizes the varying degrees of reported breakthrough bleeding. With continuous use over 126 days, 
bleeding was completely prevented in almost 40% of the women, while 60% reported at least 1 unscheduled 
bleeding day. However, typically, the bleeding was predominately light in intensity (31.6% had maximum light 
bleeding, 24.3% normal bleeding and 5.6% heavy bleeding). The first onset of bleeding occurred after a median 
of 99.0 days into the extended regimen. 
Summary statistics (median, first and third quartiles) for the diary-reported number of bleeding and/or spotting 
days are presented in Table 3. Here, the scheduled withdrawal bleeding that occurred within the first 14 days of 
the extended regimen was included in the analysis, in order to account for the total degree of bleeding per 
indicated time interval, irrespective of whether this was attributed to scheduled or unscheduled bleeding. Out of 
126 possible days, the median total number of days with bleeding was 3.0 days vs. median 9.0 days with spotting 
only. 
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Fig. 2. Percentage of all women reporting bleeding by study day. 
 
For the comparison of bleeding patterns with various forms of OC, the WHO recommends the use of fixed 
reference periods for quantification of vaginal bleeding [18]. Therefore, the bleeding data from the menstrual 
diaries were also analyzed using a 90-day reference period approach. No major difference was revealed when 
comparing the bleeding pattern reported during the 90-day or the 126-day interval. The number of bleeding-only 
days was essentially unchanged, with median 2.0 for the 90-day interval and 3.0 days for the entire 126-day 
regimen. Likewise, with continuous use over 90 or 126 days, the total number of bleeding and/or spotting days 
was also proportional to the number of days evaluated (median 13.0 vs. 17.0 days). The number of sporting-only 
days, however, seems to increase to some extent. With approximately one-and-a half times the number of 
treatment days (90 vs. 126 days), the number of sporting-only days doubles (median 4.0 vs. 9.0 days). In 
accordance with recommendations by the Food and Drug Administration, the bleeding/spotting pattern was 
further investigated by calculating the number of women with ≥7 and ≥20 days of bleeding/spotting [8]. Seven 
days or more of bleeding/spotting were observed by 55.9% of the women during 90 days and by 72% during 126 
days; 20 days or more by 27.1% and 45.2%, respectively. 
Taken together, the bleeding pattern observed during the 90-day and the 126-day interval suggests that 
breakthrough bleeding/spotting increased over time only slightly, and, typically, this shift was attributed to 
spotting only. 
3.4. Treatment acceptance 
At study exit, the women were queried about their satisfaction with the extended regimen of the EE/DRSP 
formulation (Fig. 3). The acceptance of this extended regimen was high, with 68.4% of all users giving a positive 
rating ("very much satisfied" given by 19.2%, "much" by 35.6% and "minimally" by 13.6%). Dissatisfaction was 
expressed by 21.9% of the women (with ratings of "very much dissatisfied" by 3.3%, "much" by 12.4% or 
"minimally" by 6.2%). 
When asked what type of birth control they planned to use in the future, 42.4% preferred to continue with an 
extended regimen, while 48.6% wanted to change back to a conventional 21+7-day cycle regimen, and 5.6% 
chose other options. Other options included no contraception because of wish for pregnancy (2.3%) or 
intrauterine devices (2.8%). Approximately one third of all women in the study, and the great majority of the 
women who planned to continue with an extended regimen, preferred the study regimen of 126 days, while 
approximately 10% wished to continue with an extended regimen, however, of shorter duration, e.g., 3 or 2 
months, or wanted to alternate conventional 21+7-day cycles with periods of continuous pill-intake. 
3.5. Safety 
Generally, the adverse event profile with the continuous use of the EE/DRSP formulation was similar to that 
seen with the conventional 21+7-day regimen. In this study, adverse events most frequently reported were 
symptoms associated with sinus and respiratory tract infections (typically reported as sinusitis, pharyngitis or flu 
syndrome), irregular bleeding, breast pain and headache. As expected with an extended regimen, irregular 
bleeding occurred; however, the majority of these events were rated as mild in intensity [mild in 22 (12.4%) 
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women, moderate in 10 (5.6%)] and no severe bleeding. In 19 (10.7%) of these cases, irregular bleeding led to 
premature discontinuation of study medication. A 36-year-old nonsmoking woman, who had been using OCs for 
10 years, experienced cholelithiasis requiring surgery approximately 9 months after the start of the extended 126-
day regimen. She completed study medication, followed by further COC treatment with the same marketed 
EE/DRSP formulation. 
No appreciable changes in vital signs were observed over the course of the study, nor was there any finding that 
gave cause for concern in the physical, breast or gynecological examinations at screening, end of treatment or 
withdrawal. 
In order to assess the effect of the extended administration of EE/DRSP on the endometrium, a subgroup of 30 
women at one center underwent endometrial histology sampling at completion of treatment. Only women who 
had chosen to prolong the extended regimen to a total of 252 days were selected. In eight cases, the tissue 
obtained was insufficient for diagnosis. All other endometrial biopsies were in accordance with the typical 
endometrial changes caused by a COC (in 22 of 30 women with sufficient tissue for diagnosis) and supported the 
endometrial safety of continuous use of the EE/DRSP formulation for up to 252 days. 
 
Table 2- Diary reports of bleeding profile using established criteria for bleeding intensities (full analysis set) 
Women reporting bleeding Extended cycle continuous use over 126 days (N=177) 
At least 1 bleeding day, n (%) 109 (61.6) 
   Light intensitya, n (%) 56 (31.6) 
   Normal intensitya, n (%) 43 (24.3) 
   Heavy intensitya, n (%) 10 (5.6) 
Time to first bleedingb, median days (q25, q75) 99.0 (51.0, 127.0) 
a By maximum intensity. 
b The first 14 days of the extended cycle were disregarded in order to discriminate between the scheduled withdrawal bleeding of run-in and 
the breakthrough bleeding of the  126-day cycle.  For women without any bleeding day, the time to first bleeding day was set to 127 days. 
 
Table 3- Diary reports of observed breakthrough bleeding and spotting days for all women (full analysis set; N= 
177) 
 
a In accordance with the WHO-recommended reference period of 90 days; assessing the first 90 days of the 126-day interval. 
Extended cycle continuous use over  
126 days (N=177) 90 daysa (N=177) 
Bleeding days, median (q25, q75) 3.0 (1.0, 10.0) 2.0 (0.0, 7.0) 
Spotting days, median (q25, q75) 9.0 (2.0, 21.0) 4.0 (2.0, 7.0) 
Bleeding/spotting days, median (q25, q75) 17.0 (5.0, 32.0) 13.0 (10.0, 18.0) 
   Women with ≥ 7 days, n (%) 127 (71.7) 99 (55.9) 
   Women with ≥ 20 days, n (%) 80 (45.2) 48 (27.1) 
 
4. DISCUSSION/CONCLUSION 
This large-scale, prospective study showed that the extension of the conventional 21+7-day OC cycle with a 30-
µg EE and 3-mg DRSP formulation to 126 days was safe, well accepted by the majority of users and resulted in 
considerably fewer bleeding days. With continuous use over 126 days, bleeding was completely suppressed in 
approximately 40% of the 177 women. In the 60% reporting breakthrough bleeding, a shift towards less intense 
bleeding was achieved. While the majority of women rated their monthly withdrawal bleeding as normal in 
intensity on the 21+7-day regimen, bleeding with the 126-day regimen was predominately light in intensity.             
The first onset of bleeding occurred after a median of 99.0 days into the extended cycle. 
Since 1977, when the first study on the efficacy and acceptance of long-cycle COC regimen had been carried 
out, numerous studies with different EE/progestogen combinations proved that bleeding can be reduced 
significantly while unscheduled breakthrough bleeding often increases, typically, during the first months of 
treatment [3,6,7,19]. Therefore, physicians counseling women on extended regimens and the users need to 
balance the convenience of fewer scheduled withdrawal bleeding against the inconvenience of slightly more 
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breakthrough bleeding or spotting with an extended regimen—knowing that the individual susceptibility to 
breakthrough bleeding or spotting is difficult to predict. For that reason, it is important for physicians to guide 
women on how to take and what to expect when considering the option of an extended regimen. The present 
study confirms the ability and acceptance of COC users to switch their usual 21+7-day cycles to an extended 
126-day regimen with DRSP and may help health care providers to adequately counsel their patients seeking to 
reduce the number of monthly bleedings. 
 
Fig. 3. Treatment acceptance and preferred options for future use. 
 
 
In this study, the women switched to the 126-day extended regimen after two 21+7-day run-in cycles of the same 
EE/DRSP formulation. Although it cannot be ruled out that the bleeding profile may have been positively 
affected, as no COC "starters" were included in the study (who are generally at a higher risk of unscheduled 
bleeding at the beginning), we do believe that this has no essential impact on the overall interpretation of study 
results. In contrast, the population in this study reflects both the population of other studies investigating the 
extended COC use [5,7,9,10,19] and real life of contraceptive counseling where most providers discuss the 
possibility of this regimen with COC users and most women considering an extended regimen have some 
experience with OCs. 
Our study clearly demonstrated that an OC containing EE/DRSP in an extended 126-day regimen is a suitable 
option for many women. Besides individual variation, which is commonly observed with any OC use, the 
extended 126-day regimen reduced the degree of bleeding/ spotting considerably. With continuous use of this 
EE/DRSP formulation, the women noted median 13.0 bleeding/ spotting days compared with median 18.0 days 
using the same COC in a conventional 21+7-day regimen (based on a 90-day reference period, data on file). 
In 2003, Anderson and Hait [5] reported study results of an 84+7-day COC containing 30 µg EE and 150 µ 
levonorgestrel (Seasonale®, Barr Labs, Pamona, NY, USA). This study revealed that breakthrough bleeding and/ 
or spotting decreased with every subsequent 84+7 cycles, being greatest during the first two cycles. With 
Seasonale®, women reported median 12.0 days of breakthrough bleeding/spotting during the first 84-day cycle. 
With continuous use of the EE/DRSP formulation over 90 days, the median number of bleeding/spotting was 
similar (median 13.0 vs. 12.0 days); however, the percentage of women with ≥7 or ≥20 days of bleeding/spotting 
seems lower with EE/DRSP. During the first 84 days on Seasonale®, 65% of the women experienced ≥7 days of 
bleeding/spotting vs. 55.9% of the women using the EE/DRSP formulation (Yasmin®) continuously over 90 days 
[8]. Twenty days or more were reported by 35% of the women taking Seasonale® and by 27.1% taking 
Yasmin® continuously. When compared with a 336-day extended regimen of a 20-µg EE and 100-µg 
levonorgestrel formulation, the reported number of bleeding and spotting days from Day 1 to Day 84 was similar 
to that from Day 1 to Day 126 in this study (with median 3.0 and 9.0 days, respectively) [7]. 
Moreover, the comparison between the 90-day and the 126-day interval of the extended regimen with the 
EE/DRSP formulation indicates that in the majority of women the overall degree of breakthrough 
bleeding/spotting was essentially unchanged throughout the extended 126-day cycle. Since breakthrough 
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bleeding/spotting usually diminishes with consecutive COC cycles—standard 21+7 as well as extended 
regimens—we recommend multiple extended 126-day regimens of EE/DRSP with an intervening hormone-free 
interval as a favorable treatment option. Consistently, the great majority of the women in this study who planned 
to continue with an extended regimen, preferred the study regimen, while only 10% wished to continue with an 
extended regimen of shorter duration. 
The EE/DRSP formulation used in this study is proven to be an effective and safe method of fertility control with 
cyclic OC use [13,14]. An extended COC regimen should provide better contraceptive reliability in the event of 
missed tablets due to the greater potential for sustained ovarian suppression [20]. When taken daily over 126 
days, pregnancy was prevented in all 177 women including those 19 women who missed more than two tablets 
continuously or more than four noncontinuously. 
The adverse event profile of the extended 126-day regimen was similar to that of other extended regimens and 
generally comparable to those of other COCs [5,13,14]. As expected with an extended regimen, higher rates of 
bleeding-reported events were observed compared to conventional regimens, emphasizing the need to reinforce 
this issue during counseling. The adverse event profile was also favorable in those women who had completed 
the extended 252-day regimen, although the number of women reporting complete absence of bleeding was 
reduced considerably. Endometrial histology was investigated in a small subgroup of our users. In all 22 women 
where sufficient material was available, findings were in accordance with the typical endometrial changes caused 
by a COC, providing reassurance that regular withdrawal bleedings are not necessary to prevent endometrial 
hyperplasia [21]. Similar results were found with the 336-day extended regimen of a 20-µg EE and 100-µg 
levonorgestrel formulation in which endometrial biopsies were carried out in eight women revealing inactive or 
atrophic samples in seven women [7]. 
In summary, the continuous use of a 30-µg EE and 3-mg DRSP formulation over 126 days was efficacious, well 
tolerated and resulted in considerable reduction of bleeding days. Although limited by numbers and duration of 
use, the present study confirms the extended 126-day regimen as a favorable treatment option in many women 
who desire to reduce withdrawal bleedings markedly. 
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